Mainstay Medical to Present at the 24th MedTech Investing Europe Conference

DUBLIN--()--

Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain (“CLBP”), announces that Chief Financial Officer, Hugh Kavanagh, will present at the 24th MedTech Investing Europe Conference, organised by Campden Wealth, at the Royal Savoy Hotel, Lausanne, on 5th April, 2017 from 14.15-14.25 CEST.

If you would like to meet with Mainstay management at or around this event, please contact the event organizers or investor-relations@mainstay-medical.com.

- End -

About Mainstay

Mainstay is a medical device company focused on bringing to market an innovative implantable restorative neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia and Germany, and its ordinary shares are admitted to trading on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).

About Chronic Low Back Pain

One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilise the spine in the low back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.

People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on individuals, families, communities, industry and governments.

Further information can be found at www.mainstay-medical.com

CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only.

PR and IR Enquiries:
Consilium Strategic Communications (international strategic communications – business and trade media)
Chris Gardner, Mary-Jane Elliott, Jessica Hodgson, Hendrik Thys, +44 203 709 5700 / +44 7921 697 654
mainstaymedical@consilium-comms.com
or
FTI Consulting (for Ireland)
Jonathan Neilan, +353 1 663 3686
jonathan.neilan@fticonsulting.com
or
NewCap (for France)
Julie Coulot, +33 1 44 71 20 40
jcoulot@newcap.fr
or
AndreasBohne.Com/Kötting Consulting (for Germany)
Andreas Bohne, +49 2102 1485368
abo@andreasbohne.com
or
Investor Relations:
LifeSci Advisors, LLC
Brian Ritchie, + 1-212-915-2578
britchie@lifesciadvisors.com
or
ESM Advisers:
Davy
Fergal Meegan or Barry Murphy, +353 1 679 6363
fergal.meegan@davy.ie or barry.murphy2@davy.ie

Short Name: Mainstay Medical
Category Code: STR
Sequence Number: 580803
Time of Receipt (offset from UTC): 20170330T190246+0100

Contacts

Mainstay Medical International plc

Contacts

Mainstay Medical International plc